YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Abuse Liability Assessment of l-Deprenyl by Testing Methamphetamine-like Discriminative Effects

메탐페타민 유사 분별능 시험을 통한 l-디프레닐의 약물남용가능성 평가

  • Lee, Sun-Hee (Department of Toxicology, National Institute of toxicological Research, Korea Food and Drug Administration) ;
  • Kim, Pu-Young (Department of Toxicology, National Institute of toxicological Research, Korea Food and Drug Administration)
  • 이선희 (식품의약품안전본부 독성부 특수독성과) ;
  • 김부영 (식품의약품안전본부 독성부 특수독성과)
  • Published : 1998.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

The antiparkinsonian agent l-deprenyl, a selective monoamine oxidase (MAO)-B inhibitor, is metabolized in part to l-methamphetamine and l-amphetamine. l< /I>-Deprenyl was evaluated for amphetamine and methamphetamine-like discriminative stimulus effects in rats and its mechanism of action was investigated. Rats were trained under a 5-response, fixed ratio schedule of stimulus-shock termination or a 10-response. Fixed-ratio schedule of food-presentation which discriminate between d-amphetamine (1mg/kg, i.p.) and saline or d-methamphetamine (1mg/kg, i.p.) and saline in a two-lever, operant conditioning procedure. Full generalization was obtained to d-amphetamine (1~3mg/kg). d-methamphetamine (1~3mg/kg) and l-deprenyl (17~30mg/kg) under both the food presentation and stimulus shock termination schedule. l-Deprenyl has dose-dependent amphetamine-and methamphetamine-like discriminative stimulus properties in rats only at doses of 17 and 30mg/kg. Reversible MAO-B inhibitor, RO 16-6491 didn`t show any amphetamine-like discriminative properties. Aromatic amino acid decarboxylase inhibitor, NSD 1015 decreased % responding of l-deprenyl in the methamphetamine-trained rats under the stimulus-shock termination schedule. SKF-525A produced partial inhibition of methamphetamine-like discriminative effects of l-deprenyl under the food presentation schedule. These results suggest that l-deprenyl has no abuse liability at the therapeutic range but there needs some caution at high doses and furthermore, drug discrimination studies under the food presentation and shock termination schedule are useful for the assessment of abuse liability of psychostimulants.

Keywords

References

  1. N. Eng. J. Med. v.321 Effect of deprenyl on the progression of disability in early Parkinson's disease The Parkinson study group
  2. Acta. Neurol. Scand. v.126 Strategy and tactic of modern Parkinson therapy Birkmayer, W.;Birkmayer, G. J. D.
  3. J. Pharmacol. Exp. Ther. v.259 no.2 Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites: Effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons Engberg, G.;Elebring, T.;Nissbrandt, H.
  4. J. Pharm. Pharmac. v.17 Urianry kinetics of methylamphetamine in man Beckett, A. H.;Rowland M.
  5. J. Pharmacol. Exp. Ther. v.265 no.1 Evaluation of stereoisomers of deprenyl for amphetamine-like discriminative stimulus in rats Yasar, S.;Schindler, C. W.;Thorndike, E. B.;Szelenyi;Goldberg, S. R.
  6. Eur. J. Pharmacol. v.259 Evaluation of deprenyl for cocaine-like discriminative stimulus effects in rats Yasar, S.;Schindler, C. W.;Thorndike, E. B.;Goldberg, S. R.
  7. Naunyn-Schmiedeberg's Arch. Pharmacol. v.275 Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo using an inhibitor of the aromatic amino acid decarboxylase Carlsson, A.;Davis, J. N.;Kehr, W.;Lindqvist, M.;Atack, C. V.
  8. Clin. Pharmacol. Ther. v.56 Amphetamine-like effect of l-deprenyl(selegiline) in drug discrimination studies Yasar, S.;Bergman, J.
  9. J. Pharmacol. Exp. Ther. v.257 Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections Witkin, J. M.;Nichols, D. E.;Terry, P.;Katz, J. L.
  10. Br. J. Clin. Pharmacol. v.6 Deprenyl is metabolized to methamphetamine and amphetamine in man Reynolds, G. P.;Elsworth, J. D.;Blau, K.;Sandler, M.;Less, A. J.;Stern, G. M.
  11. J. Pharm. Pharmacol. v.31 Amphetamine, p-hydroxyamphetamine and beta-phenylethylamine in mouse brain and urine after (-)- and (+)-deprenyl administration Phillips, S. R.
  12. Neurotoxicology v.32 Metabolism of d, l-deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit : A biochemical assessment Karoum, F.;Chuang, L.;Eisler, T.;Calne, D. B.;Liebowitz, M. R.;Quitkin, F. M.;Klein, D. F.;Wyatt, R. J.
  13. Psychopharmacology v.101 Generalization of ;-deprenyl, but not MDL-72974, to the d-amphetamine stimulus in rats Moser, P. C.
  14. Neuropharmacology v.23 Discrimination of the amphetamine cue: Effects of A, B and mixed type inhibitors of monoamine oxidase Porsolt, R. D.;Pawelec, C.;Jalfre, M.
  15. Biochem. Pharmacol. v.36 Effects of different monoamine oxidase inhibitors on the metabolism of l-DOPA in the rat brain Buu, N. T.;Angers, M.
  16. Clin. Pharmacol. Ther. v.56 Intravenous self-administration studies with l-deprenyl (selegiline) in monkeys Winger, G. D.;Yasar, S.;Negus, S. S.;Goldberg, S. R.